Literature DB >> 12764388

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera.

R T Silver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12764388     DOI： 10.1038/sj.leu.2402938

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.

Authors:  Zhe Li; Mingjiang Xu; Shu Xing; Wanting Tina Ho; Takefumi Ishii; Qingshan Li; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

2.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 3.  Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

Authors:  David Dingli; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.

Authors:  Roberto H Nussenzveig; Jorge Cortes; Matjaz Sever; Alfonso Quintás-Cardama; Pat Ault; Taghi Manshouri; Carlos Bueso-Ramos; Josef T Prchal; Hagop Kantarjian; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

Review 6.  Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Authors:  Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

7.  Phase II open label trial of imatinib in polycythemia rubra vera.

Authors:  C Michael Jones; Tina M Dickinson; August Salvado
Journal:  Int J Hematol       Date:  2008-11-15       Impact factor: 2.490

Review 8.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

9.  In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.

Authors:  P B Soares; T S Jeremias; M Alvarez-Silva; M A Licinio; M C Santos-Silva; C L Vituri
Journal:  Braz J Med Biol Res       Date:  2012-09-25       Impact factor: 2.590

10.  Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.